Clinical research
Karyopharm Therapeutics posted positive Phase III results in multiple myeloma and announced it is planning a regulatory submission in the second quarter of this year for its combination of Xpovio, Velcade and Dexamethasone.
EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second Phase III trial of Yutiq (fluocinolone acetonide intravitreal implant) for treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Abivax SA announced dosing of the first patient in a U.S. Phase 1/2 clinical trial of ABX196 to treat patients with hepatocellular carcinoma, the most common form of liver cancer..
The randomized, open-label, multicenter studies will enroll about 1,000 patients mostly in Asia, as well as in countries that have had high numbers of diagnosed cases. The trials are planned to start in March.
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders.
A federal judge has ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved, must now be made public.
Data position the company to start potential registrational trials with two drugs in two tumor types
BioSpace takes a look at some of the investigational products that could, one day, provide relief for migraine sufferers.
Exblifep is a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and the fourth-generation cephalosporin cefepime.
PRESS RELEASES